Efficacy of short-term growth hormone treatment in prepubertal children with idiopathic short stature.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

The present study aimed to validate the GH (Eutropin®) effect on growth promotion and safety after short-term GH treatment.

Who Took Part

PubMed indexes the participants as children, both men and women.

Thirty six prepubertal children with ISS were enrolled in this study to receive 6-month GH treatment.

Yearly growth rate, height standard deviation score (SDS), and adverse events were investigated during treatment.

How the Study Was Run

In design terms this was an open-label and multicenter study.

Everyone knew when Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

More than one site took part, so the participants came from several places.

This study was an open-label, multicenter, interventional study conducted at nine university hospitals in Korea between 2008 and 2009.

What Was Measured

The subject headings attached to it are Growth Disorders, Growth Hormone, Insulin-Like Growth Factor Binding Protein 3 and Insulin-Like Growth Factor I.

Author keywords: Treatment outcome, child, idiopathic, safety and short stature.

What This Means in Plain Language

The paper is an open-label and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (Yonsei medical journal), a journal based in Korea (South).

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.